Hepatitis

People in the European Union with acute hepatitis C virus (HCV) infections now have a new treatment option: Abbvie’s Maviret (glecaprevir/pibrentasvir). EU regulators have…

Among people with chronic hepatitis D (CHD) infection, combination treatment regimens containing lonafarnib show benefits in easing disease burden and improving liver health. Specifically,…

The Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approval of Abbvie’s oral therapy Maviret (glecaprevir/pibrentasvir) to cover its use…

Nearly one in five people with chronic hepatitis B who were given add-on treatment with GlaxoSmithKline (GSK)’s bepirovirsen in two global clinical trials…

PBGENE-HBV, Precision Biosciences’ experimental gene-editing therapy for chronic hepatitis B, showed early evidence of eliminating and inactivating hepatitis B viral DNA as designed,…

Assembly Biosciences plans to develop its investigational oral treatment, ABI-6250, for people with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC). The…

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Hepcludex (bulevirtide-gmod), in development by Gilead Sciences, for treating adults with…

A large clinical trial evaluating Atea Pharmaceuticals’ fixed-dose oral combination of bemnifosbuvir and ruzasvir in adults with chronic hepatitis C remains on track,…

GlaxoSmithKline (GSK) has submitted an application to Health Canada seeking approval of its chronic hepatitis B therapy bepirovirsen for treating adults with the…

This article was provided by our partner, the American Liver Foundation. It has been reviewed by Bionews for accuracy and…